Adoption of a Newly Introduced Dermal Matrix: Preliminary Experience and Future Directions

Abstract EN

Introduction.

Acellular dermal matrix (ADM) products are adopted in the management of injuries to soft tissues.

ADMs have been increasingly employed for their clinical advantages, and they are acquiring relevance in the future of plastic surgery.

The aim of our study is to evaluate the application of ADMs in our patients who could not undergo fast reconstruction.

Materials and Methods.

We performed a retrospective study on 12 patients who underwent ADM placement for scalp and limb surgical reconstructions at the Humanitas Research Hospital, Rozzano (Milano), Italy.

Wounds resulted from 9 tumor resections and 3 chronic ulcers.

The ADM substrate used to treat these lesions was PELNAC™ (Gunze, Japan), a double-layered matrix composed of atelocollagen porcine tendon and silicon reinforcement.

All patients underwent a second surgical operation to complete the treatment with a full-thickness skin graft to cover the lesion.

Results.

In this study, 12 patients were treated with PELNAC™: 11 out of 12 patients showed a good attachment over a median time of 21.3 days (range 14-27).

After almost 23 days, all patients were ready to undergo a full-thickness skin grafting.

Conclusion.

This study assesses the benefits of PELNAC™ and proposes this method as an alternative to traditional approaches, especially in situations where the latter techniques cannot be applied.